India
· Delayed Price · Currency is INR Suven Life Sciences Statistics
Total Valuation
Suven Life Sciences has a market cap or net worth of INR 26.13 billion. The enterprise value is 24.46 billion.
| Market Cap | 26.13B |
| Enterprise Value | 24.46B |
Important Dates
The last earnings date was Friday, October 25, 2024.
| Earnings Date | Oct 25, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Suven Life Sciences has 218.07 million shares outstanding. The number of shares has increased by 1.84% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 218.07M |
| Shares Change (YoY) | +1.84% |
| Shares Change (QoQ) | +0.61% |
| Owned by Insiders (%) | 2.27% |
| Owned by Institutions (%) | 15.52% |
| Float | 57.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 13.60 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -16.76 |
| EV / Sales | 290.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -16.48 |
Financial Position
The company has a current ratio of 10.40, with a Debt / Equity ratio of 0.00.
| Current Ratio | 10.40 |
| Quick Ratio | 9.50 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | -1,587.17 |
Financial Efficiency
Return on equity (ROE) is -54.98% and return on invested capital (ROIC) is -38.75%.
| Return on Equity (ROE) | -54.98% |
| Return on Assets (ROA) | -36.70% |
| Return on Capital (ROIC) | -38.75% |
| Revenue Per Employee | 596,801 |
| Profits Per Employee | -10.35M |
| Employee Count | 141 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 1.14 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +40.04% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +40.04% |
| 50-Day Moving Average | 137.40 |
| 200-Day Moving Average | 119.93 |
| Relative Strength Index (RSI) | 40.27 |
| Average Volume (20 Days) | 25,197 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Suven Life Sciences had revenue of INR 84.15 million and -1.46 billion in losses. Loss per share was -6.69.
| Revenue | 84.15M |
| Gross Profit | 75.91M |
| Operating Income | -1.65B |
| Pretax Income | -1.47B |
| Net Income | -1.46B |
| EBITDA | -1.60B |
| EBIT | -1.65B |
| Loss Per Share | -6.69 |
Balance Sheet
The company has 1.66 billion in cash and 2.44 million in debt, giving a net cash position of 1.66 billion or 7.62 per share.
| Cash & Cash Equivalents | 1.66B |
| Total Debt | 2.44M |
| Net Cash | 1.66B |
| Net Cash Per Share | 7.62 |
| Equity (Book Value) | 1.93B |
| Book Value Per Share | 8.81 |
| Working Capital | 1.69B |
Cash Flow
In the last 12 months, operating cash flow was -1.49 billion and capital expenditures 3.43 million, giving a free cash flow of -1.48 billion.
| Operating Cash Flow | -1.49B |
| Capital Expenditures | 3.43M |
| Free Cash Flow | -1.48B |
| FCF Per Share | -6.81 |
Margins
| Gross Margin | 90.20% |
| Operating Margin | -1,961.59% |
| Pretax Margin | -1,746.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -1,764.02% |
Dividends & Yields
Suven Life Sciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.84% |
| Shareholder Yield | -1.84% |
| Earnings Yield | -5.58% |
| FCF Yield | -5.68% |
Stock Splits
The last stock split was on March 23, 2007. It was a forward split with a ratio of 4.
| Last Split Date | Mar 23, 2007 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |